Abstract
Isoniazid (INH) is a prodrug activated by the mycobacterial enzyme KatG, a multifunctional catalase peroxidase. KatG converts INH to reactive antimycobacterial species. For decades, an association between INH and drug-induced lupus erythematosus has been recognized. We present the case of a patient with primary progressive multiple sclerosis whose disease commenced weeks after initiating INH therapy for prevention of tuberculosis. Possible mechanisms by which INH may trigger autoimmunity in humans are discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 253-256 |
Number of pages | 4 |
Journal | Therapeutic Advances in Neurological Disorders |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2014 |
Externally published | Yes |
Keywords
- Autoimmunity
- Isoniazid
- Multiple Sclerosis
ASJC Scopus subject areas
- Pharmacology
- Neurology
- Clinical Neurology